Athenex Inc. (ATNX) and Kura Oncology Inc. (NASDAQ:KURA) Contrasting side by side

Athenex Inc. (NASDAQ:ATNX) and Kura Oncology Inc. (NASDAQ:KURA) compete with each other in the Biotechnology sector. We will analyze and compare their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Athenex Inc. 82.70M 9.94 118.61M -1.29 0.00
Kura Oncology Inc. N/A 0.00 55.10M -1.67 0.00

Table 1 shows gross revenue, earnings per share and valuation of the two companies.


Table 2 represents Athenex Inc. (NASDAQ:ATNX) and Kura Oncology Inc. (NASDAQ:KURA)’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Athenex Inc. -143.42% -89.2% -62.5%
Kura Oncology Inc. 0.00% -44.8% -39.5%


The Current Ratio of Athenex Inc. is 4.5 while its Quick Ratio stands at 3.9. The Current Ratio of rival Kura Oncology Inc. is 14.8 and its Quick Ratio is has 14.8. Kura Oncology Inc. is better equipped to clear short and long-term obligations than Athenex Inc.

Insider & Institutional Ownership

Institutional investors held 25.3% of Athenex Inc. shares and 77.3% of Kura Oncology Inc. shares. Insiders held roughly 8% of Athenex Inc.’s shares. Competitively, Kura Oncology Inc. has 10.8% of it’s share held by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Athenex Inc. -5.75% -0.08% -20.94% -25.61% -20.69% -21.64%
Kura Oncology Inc. 8.82% 14.31% -26.88% -19.18% -2.33% -9.67%

For the past year Athenex Inc. was more bearish than Kura Oncology Inc.


On 6 of the 9 factors Kura Oncology Inc. beats Athenex Inc.

Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer. Its Orascovery product candidates include Oraxol, an oral dosage form, which is in a Phase III trial in metastatic breast cancer for the treatment of advanced gastric cancer; Oratecan, an anticancer agent that is in a Phase 1 study for the treatment of colorectal, lung, ovarian, cervical, pancreatic, upper gastrointestinal, and brain cancer; Oradoxel, an anticancer agent, which is in a Phase 1 clinical study in the treatment of breast, prostate, gastric, head and neck, and lung cancer; and Oratopo, an anticancer for the treatment of cervical, ovarian ,and lung cancer. The company also develops KX-01, a compound, which is in Phase 3 study for the treatment of for actinic keratosis; and KX-02 for the treatment of gliomas. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was founded in 2003 and is based in Buffalo, New York.

Kura Oncology, Inc., a clinical stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The companyÂ’s lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, lower risk myelodysplastic syndromes, and chronic myelomonocytic leukemia. It also develops KO-947, a small molecule inhibitor of extracellular signal related kinase used for the treatment for patients with tumors that have mutations in, or other dysregulation of, the mitogen-activated protein kinase; and KO-539, a small molecule inhibitor of the menin-mixed lineage leukemia. The company was founded in 2014 and is headquartered in La Jolla, California.